Overview

Chronic obstructive pulmonary disease (COPD) is a highly prevalent chronic condition. While COPD is a lung disease, it is mainly the exacerbations and extrapulmonary comorbidities which affect the quality of life, health care costs, and prognosis. The optimal COPD treatment needs to focus on both the characteristics and consequences of the lung disease itself and the diagnosis and treatment of comorbidities. While the severity of lung function impairment is routinely assessed, the exacerbations, the associated comorbidities and limitations in daily life are still significantly underestimated. A personalized approach to COPD management is needed to specifically address the disease, prevent exacerbations, and mitigate its comorbidities to obtain a positive impact on patient health and quality of life. TOLIFE will clinically validate an artificial intelligence (AI) solution to process daily life patient data captured by unobtrusive sensors to enable optimised personalised treatment, assessment of health outcomes and improved quality of life in COPD patients. The TOLIFE approach has the potential to reduce mortality, improve health related quality of life and reduce the healthcare costs. TOLIFE will develop and clinically validate an AI-based platform for the early prediction of exacerbations and assessment of the health outcomes that will be exploited by clinicians through a patient management tool to perform early and personalized treatment. TOLIFE platform will inform through a disease information tool the patient and caregivers about the patient's health status, the specific treatment plan and lifestyle indications. Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.